A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
about
The Hawthorne Effect: a randomised, controlled trialStroke, dementia, and drug deliveryMaintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapyLong-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianDonepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.Cognition enhancers for the treatment of dementia.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Treatment of dementia with neurotransmission modulation.Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.A systematic mapping review of randomized controlled trials (RCTs) in care homesA Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.Psychosis in elderly patients: classification and pharmacotherapy.The safety and tolerability of donepezil in patients with Alzheimer's disease.Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalitiesEfficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilitiesDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsA systematic review of assessment and treatment of moderate to severe Alzheimer's disease.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.Reliability of peak treadmill exercise tests in mild Alzheimer disease.Clinically tested drugs for Alzheimer's disease.Non-pharmacological interventions in cognitively impaired and demented patients--a comparison with cholinesterase inhibitors.Emerging therapeutics for Alzheimer's disease: an avenue of hope.Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Citalopram for agitation in Alzheimer's disease: design and methods.Elder-Clowning in Long-Term Dementia Care: Results of a Pilot Study.Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease.Pharmacologic treatment of adolescent and child schizophrenia.Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's studyTreatments for behavioural disorders in neurodegenerative diseases: drug development strategies.Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
P2860
Q21261930-351E2F52-4577-4277-B818-CE443F7E2358Q28166505-3ADEE1E6-F99F-4244-9555-F89A756E720FQ30432684-F349F815-5A1D-4B27-99F7-523945C2A86DQ30433785-08A13D0D-2272-472B-A8B6-8BF6E9E4CA19Q30436664-58CBB9CD-FC11-4E2A-9785-5579CFD97689Q30872331-A702900E-A19C-4BBE-BDE4-09BB5A77272EQ33160127-DF9E00DE-6A71-4185-9262-985363AC41BAQ33165693-581D0BB4-12BA-4BDF-829D-364D6D2B2EF7Q33599473-BCA14C11-EDD1-4A15-9F97-E32090B0B3A7Q33912750-EF5B5D98-B98A-4BD2-A864-E1565A266656Q33928316-96E7E5A7-201A-44F3-B325-FE90111D8F2EQ34266258-E94261EB-3C19-4CB2-A8FD-C75E03AFD53EQ34297733-12D40270-FE7B-481E-A72A-0F7A7CE62F7CQ34316513-69ECFEB5-301D-40F2-9BDC-25FB4E13BD45Q34318028-24DE236A-1D3E-49BE-92A7-BA61E7DCED47Q34452896-16DB323B-1360-495C-8DC9-685028E3BC4FQ34463351-8A229C4F-9428-4800-AF4E-67DD97B0A5C0Q34543627-CDBBD1AA-5CFB-48EA-BD23-92D54D6953FDQ34552035-DCDCEE1E-CBB4-415C-AEF4-FAA448EF52A1Q34552380-CA278125-2087-4C8E-A47E-156C9C1803EFQ34648742-2CCD408C-0CCC-4DB5-A076-4230E8CABDB3Q34789455-2BDAC635-7C61-4216-A1CC-76E02FB5DDB3Q34965949-B37E91F0-B765-404F-A361-E2E817BCD34DQ34977044-AC67AB0B-D8CF-44BE-B37E-18C605FBCB21Q34987695-DA9C6E20-BC7D-4485-B64D-29F8E0365158Q35112092-26ED20D0-8BE2-4B1F-835E-6AF95F97B630Q35126819-F3ACC675-9050-4537-B368-7470DE86A55FQ35164747-167FC521-E26F-4398-8319-B8C77F3E53C3Q35593781-095F90A2-4CBD-4A80-A331-9970C9555254Q35618922-5ECA4E81-9C56-49B4-BC5D-661EEAA4047AQ35826258-0D459604-EABC-40D2-9D9D-BA73131A0D8AQ35876403-EB9F9A21-AFFB-435F-981C-0AAD713267E3Q35905635-7888CB47-EF32-4871-A815-E23E8EA945BCQ35927033-662046CB-E953-45D2-A8B7-C92B3D429FC9Q36036556-060CDF65-0DA4-448B-9A6B-1B0A95C81E7CQ36107249-7C259C93-EF9C-421B-B5EB-A0DECC267C35Q36247233-93ACB52C-368F-4E8A-A7C2-7DED71A99B07Q36399561-3E467946-146D-4000-8CD1-58A04E839AA3Q36458299-31A88E89-443C-4D96-B1B2-65E636DBEF76Q36513610-3654BACD-FE54-4DFD-BB68-ED8FCB7475B4
P2860
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... e in the nursing home setting.
@en
A randomized, double-blind, pl ...... e in the nursing home setting.
@nl
type
label
A randomized, double-blind, pl ...... e in the nursing home setting.
@en
A randomized, double-blind, pl ...... e in the nursing home setting.
@nl
prefLabel
A randomized, double-blind, pl ...... e in the nursing home setting.
@en
A randomized, double-blind, pl ...... e in the nursing home setting.
@nl
P2093
P2860
P921
P1476
A randomized, double-blind, pl ...... e in the nursing home setting.
@en
P2093
Cummings JL
Perdomo CA
P2860
P304
P356
10.1111/J.1532-5415.2001.49266.X
P407
P577
2001-12-01T00:00:00Z